Vazkepa: ‘Constructive Discussions' Help Amarin Win Reimbursement For ‘Hundreds Of Thousands’ In UK
Reimbursement Discussions Progressing In Other European Markets
Executive Summary
Amarin’s drug, which costs £144.21 for a 30-day supply, is to be made available on the National Health Service in England and Wales for reducing the risk of cardiovascular events after NICE reversed its previous rejection of the product.
You may also be interested in...
Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.
Sweden Says Yes To Vazkepa Reimbursement But England Says No For Now
Amarin’s treatment is to be made available in Sweden for cardiovascular risk reduction at a price of SEK1,640 per month. But England’s health technology assessment body has concerns over the drug’s cost effectiveness.
Hikma Is Prepared For Tougher Pricing Environment In 2022
Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.